Ogden Christopher 4

What Happened
Christopher Ogden, Chief Financial Officer of CytomX Therapeutics (CTMX), sold 19,323 shares on 2026-03-17 at $6.42 per share, generating proceeds of about $124,112. This was a sale (not a purchase) and was executed to satisfy tax or other government withholding obligations related to the vesting of restricted stock units (RSUs).

Key Details

• Transaction date and price: 2026-03-17 — 19,323 shares sold at $6.42 each.
• Total proceeds: approximately $124,112.
• Reason/footnote: F1 — shares sold solely to satisfy tax or other government withholding on RSU vesting.
• Ownership note: F2 — filing references 173,082 RSUs; the filing excerpt provided does not state the total shares owned following the transaction.
• Filing timeliness: Report filed 2026-03-19 for a 2026-03-17 transaction; filing appears timely (no late-file flag noted).
• Transaction code: S (sale); withholding/tax code noted (F).

Context
This was a routine, tax-related disposition tied to RSU vesting (common when executives have shares withheld or sold to cover taxes). Such transactions typically reflect tax-management activity rather than an explicit signal about the insider’s view of the company.